Mga Batayang Estadistika
| CIK | 1398733 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aquestive Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
adcompressrelease-9x3x25 Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™ • NDA remains on track for FDA PDUFA goal date of January 31, 2026 • Commercial planning continues enabling rapid launch following approval WARREN, N. |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2025 Aquestive Therapeutics, Inc. |
|
| August 15, 2025 |
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock Exhibit 99.2 Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock WARREN, N.J., August 14, 2025 – Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an u |
|
| August 15, 2025 |
Exhibit 1.1 Execution Version Aquestive Therapeutics, Inc. (a Delaware corporation) 21,250,000 Shares of Common Stock UNDERWRITING AGREEMENT August 14, 2025 Leerink Partners LLC Cantor Fitzgerald & Co. Oppenheimer & Co. Inc. as Representatives of the several Underwriters c/o Leerink Partners LLC 1301 Avenue of the Americas 5th Floor New York, New York 10019 c/o Cantor Fitzgerald & Co. 110 East 59t |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 Aquestive Therapeutics, Inc. |
|
| August 15, 2025 |
Project Academy Corporate Presentation Strictly Confidential. Do Not Distribute. Exhibit 99.1 Project Academy Corporate Presentation Strictly Confidential. Do Not Distribute. Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” or “us”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “ant |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 Aquestive Therapeutics, Inc. |
|
| August 14, 2025 |
Exhibit 99.1 Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film • Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions • Strategic financing will further strengthen the Company’s balance sheet in advance of potential commercialization of An |
|
| August 14, 2025 |
21,250,000 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-278498 PROSPECTUS SUPPLEMENT (To Prospectus dated April 23, 2024) 21,250,000 Shares Common Stock We are offering 21,250,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “AQST.” On August 13, 2025, the last reported sale price of our |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2025 Aquestive Therapeutics, Inc. |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therapeutic |
|
| August 11, 2025 |
q22025supplementalearnin Advancing medicines. Solving problems. Improving lives. September 2024 Second Quarter 2025 Earnings Supplemental Materials August 11, 2025 © 2025 Aquestive Therapeutics, Inc. 2 Disclaimer Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticip |
|
| August 11, 2025 |
aquestivecorppresentati Advancing medicines. Solving problems. Improving lives. September 2024 Corporate Presentation August 2025 © 2025 Aquestive Therapeutics, Inc. 2 Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” or “us”) and contains forward-looking statements within the meaning of the Priva |
|
| August 11, 2025 |
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update •FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 •Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA •Company accelerates Anaphylm global expansion strategy to Canada and the EU •Company to host investor call on August 12, 2025, |
|
| July 15, 2025 |
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film • New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025 • Initial briefing book submitted for review to the European Medicines Agency WARREN, N. |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2025 Aquestive Therapeutics, Inc. |
|
| June 16, 2025 |
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions • FDA assigns PDUFA target action date of January 31, 2026 WARREN, N. |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2025 Aquestive Therapeutics, Inc. |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2025 Aquestive Therapeutics, Inc. |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2025 Aquestive Therapeutics, Inc. |
|
| June 2, 2025 |
Advancing medicines. Solving problems. Improving lives. September 2024 Corporate Presentation June 2025 © 2025 Aquestive Therapeutics, Inc. 2 Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” or “us”) and contains forward-looking statements within the meaning of the Private Securities Litigation R |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 Aquestive Therapeutics, Inc. |
|
| May 12, 2025 |
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update •Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions •Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval •Company to host investor call on May 13, 2025, at 8:00 |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therapeuti |
|
| May 12, 2025 |
CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is effective as of January 1, 2025 (the “Effective Date”) and hereby confirms the engagement by Aquestive Therapeutics, Inc. |
|
| May 12, 2025 |
Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. First Quarter 2025 Earnings Supplemental Materials May 12, 2025 © 2025 Aquestive Therapeutics, Inc. 2 ® Disclaimer Certain statements in this press release include “forward-looking statements” within the meaning of th |
|
| April 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 1, 2025 |
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance expected in Q2 2025 WARREN, N. |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2025 Aquestive Therapeutics, Inc. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2025 Aquestive Therapeutics, Inc. |
|
| March 10, 2025 |
Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Corporate Presentation March 2025 © 2025 Aquestive Therapeutics, Inc. 2 This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” or “ |
|
| March 5, 2025 |
AQUESTIVE THERAPEUTICS, INC. INSIDER TRADING POLICY (Amendment Approved by Board, Effective October 19, 2023) The purpose of this policy (the “Policy”) o f Aquestive Therapeutics, Inc. (the “Company”) is to establish Company policy and expectations with respect to compliance with securities laws and regulations relating to trading in Company securities, as well as trading in the securities of othe |
|
| March 5, 2025 |
Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Fourth Quarter and Full Year 2024 Earnings Supplemental Materials March 5, 2025 © 2025 Aquestive Therapeutics, Inc. 2 ® Disclaimer Certain statements in this press release include “forward-looking statements” within t |
|
| March 5, 2025 |
Exhibit 99.1 Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update •Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDA •Anaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDA •Initial Anaphylm pediatric clinical trial results in subjects 7-17 years of age in line with expec |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2025 Aquestive Therapeutics, Inc. |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Ther |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110233.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Aquestive Therapeutics, Inc. and further agree that |
|
| February 12, 2025 |
a2025-2x10aaaaimeetingda Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting • Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersion • New findings demonstrate dosing of Anaphylm results in consistent epinephrine absorption without impacting safety or pharmacodynamic (PD) parameters • Anaphylm pharmacokinetic (PK) and PD are not impacted by oral swelling • Median symptom resolution time was 12 minutes compared to 74 minutes without treatment; mean angioedema symptom resolution time was within 5 minutes. |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2025 Aquestive Therapeutics, Inc. |
|
| January 24, 2025 |
As filed with the Securities and Exchange Commission on January 24, 2025 As filed with the Securities and Exchange Commission on January 24, 2025 Registration No. |
|
| January 24, 2025 |
Exhibit 24.1 POWER OF ATTORNEY KNOW TO ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel R. Barber, A. Ernest Toth, Jr. and Lori J. Braender, and each or any one of them, as such person’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person’s name, place and ste |
|
| January 24, 2025 |
Filing Fee Table, filed herewith. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aquestive Therapeutics, Inc. |
|
| January 13, 2025 |
aqstbusinessupdate2025-f Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives • On track to submit Anaphylm™ (epinephrine) Sublingual Film NDA in Q1 2025 • Actively recruiting subjects in the Anaphylm pediatric clinical trial • Successfully completed AQST-108 (epinephrine) Topical Gel pre-IND meeting and on track to begin Phase 2a clinical trial in alopecia areata in Q2 2025 • Unaudited cash and cash equivalents of approximately $70 million as of December 31, 2024 WARREN, N. |
|
| January 13, 2025 |
Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. 1 Corporate Presentation January 2025 © 2025 Aquestive Therapeutics, Inc. 2 This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 Aquestive Therapeutics, Inc. |
|
| December 19, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2024 Aquestive Therapeutics, Inc. |
|
| December 19, 2024 |
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five • U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States for the treatment of seizure clusters in patients ages 2 to 5 WARREN, N.J., December 19, 2024 - Aqu |
|
| December 2, 2024 |
q42024-prexndameetingsup Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. 1 Anaphylm Pre-NDA Meeting Supplemental Material December 2, 2024 © 2024 Aquestive Therapeutics, Inc. 2 ® Disclaimer This presentation has been prepared by Aquestive Therapeutics, Inc. (“Aques |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2024 Aquestive Therapeutics, Inc. |
|
| December 2, 2024 |
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film • Reaffirms New Drug Application (NDA) first quarter 2025 submission guidance • Confirms no additional adult clinical trials are necessary prior to NDA submission • Commenced pediatric trial in the U. |
|
| November 14, 2024 |
AQST / Aquestive Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-aqst093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aquestive Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03843E104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2024 Aquestive Therapeutics, Inc. |
|
| November 6, 2024 |
Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. 1 Corporate Presentation November 2024 © 2024 Aquestive Therapeutics, Inc. 2 This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 Aquestive Therapeutics, Inc. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2024 Aquestive Therapeutics, Inc. |
|
| November 4, 2024 |
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update •Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024 • AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024 • Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channels • Finis |
|
| November 4, 2024 |
120172535.2 AMENDED AND RESTATED BYLAWS OF AQUESTIVE THERAPEUTICS, INC. (As of October 16, 2024) ARTICLE I STOCKHOLDERS Section 1. The annual meeting of the stockholders of Aquestive Therapeutics, Inc. (the “Corporation”) for the purpose of electing directors and for the transaction of such other business as may properly be brought before the meeting shall be held on such date, and at such time an |
|
| November 4, 2024 |
Advancing medicines. Solving problems. Improving lives. September 2024 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. 1 Third Quarter 2024 Earnings Supplemental Materials November 4, 2024 © 2024 Aquestive Therapeutics, Inc. 2 ® Disclaimer Certain statements in this presentation include “forward-looking statements” within the meaning |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therap |
|
| October 25, 2024 |
Sublingual Epinephrine Film's Mucoadhesive Properties Ensures Consistent Oral Placement and Drug Release Carl Kraus MD1, David Golden MD2, Matt Greenhawt MD3, Jay Lieberman MD4, David Bernstein MD5, John Oppenheimer MD6, Steve Wargacki PhD1 1Aquestive Therapeutics, Inc. |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2024 Aquestive Therapeutics, Inc. |
|
| October 25, 2024 |
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting • Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injection • Data demonstrates Anaphylm offers a consistent and permissive method of drug delivery in anaphylaxis management WARREN, N. |
|
| October 25, 2024 |
SUBLINGUAL EPINEPHRINE FILM'S MUCOADHESIVE PROPERTIES ENSURE CONSISTENT ORAL PLACEMENT AND DRUG RELEASE Carl Kraus MD1, David Golden MD2, Matt Greenhawt MD3, Jay Lieberman MD4, David Bernstein MD5, John Oppenheimer MD6, Steve Wargacki PhD1 1Aquestive Therapeutics, 2Medstar Franklin Square Hospital, Baltimore, MD, 3Children's Hospital Colorado, University of Colorado, Aurora, CO, 4University of Tennessee Health Science Center, Memphis, TN, 5Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, 6UMDNJ Rutgers University School of Medicine INTRODUCTION • Epinephrine administered intramuscularly into the anterolateral thigh via manual injection or auto-injector (e. |
|
| October 24, 2024 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Anaphylm (epinephrine) Sublingual Film Oral Allergy Syndrome Challenge Study Supplemental Materials October 24, 2024 1 Advancing medicines. Solving problems. Improving lives. 2 ® Disclaimer Certain statements in this presentation include “forward-looking statements” within the meaning of |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2024 Aquestive Therapeutics, Inc. |
|
| October 24, 2024 |
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film • Completed OAS challenge study meets both primary and secondary endpoints • Demonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration • Pharmacokinetic (PK) profile after allergen exposure comparable to non-allergen PK profile • On track for a pre-NDA meeting on Anaphylm in Q4 2024 WARREN, N. |
|
| October 16, 2024 |
120172535.2 AMENDED AND RESTATED BYLAWS OF AQUESTIVE THERAPEUTICS, INC. [As of February 2, 2023]October 16, 2024 ARTICLE I STOCKHOLDERS Section 1. The annual meeting of the stockholders of Aquestive Therapeutics, Inc. (the “Corporation”) for the purpose of electing directors and for the transaction of such other business as may properly be brought before the meeting shall be held on such date, and |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2024 Aquestive Therapeutics, Inc. |
|
| September 27, 2024 |
investordaypresentation9 Adrenaverse Prodrug Platform Investor Day September 27, 2024 Disclaimer 2 © 2024 Aquestive Therapeutics, Inc. |
|
| September 27, 2024 |
aquestiveinvestordayreca Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day • Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film • Outlines the development strategy for the Company’s next pipeline product candidate, AQST-108 (epinephrine) Topical Gel for the treatment of Alopecia areata • Holds virtual investor day WARREN, N. |
|
| September 27, 2024 |
corporatepresentation9-2 Advancing medicines. Solving problems. Improving lives. 1 Advancing medicines. Solving problems. Improving lives. Corporate Presentation September 2024 Disclaimer © 2024 Aquestive Therapeutics, Inc. This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” or “us”) and contains forward-looki |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 27, 2024 Aquestive Therapeutics, Inc. |
|
| September 9, 2024 |
hcwainwright-september20 Advancing medicines. Solving problems. Improving lives. 1 Advancing medicines. Solving problems. Improving lives. H.C. Wainwright 26th Annual Global Investor Conference September 9, 2024 Advancing medicines. Solving problems. Improving lives. Disclaimer 2 © 2024 Aquestive Therapeutics, Inc. This presentation and the accompanying oral commentary have been prepared by Aquest |
|
| September 9, 2024 |
corporatepresentation9-7 Advancing medicines. Solving problems. Improving lives. 1 Advancing medicines. Solving problems. Improving lives. Corporate Presentation September 2024 Disclaimer 2 © 2024 Aquestive Therapeutics, Inc. This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” or “us”) and contains forward-loo |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2024 Aquestive Therapeutics, Inc. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2024 Aquestive Therapeutics, Inc. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therapeutic |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 Aquestive Therapeutics, Inc. |
|
| August 6, 2024 |
Advancing medicines. Solving problems. Improving lives. Second Quarter 2024 Earnings Supplemental Materials August 6, 2024 1 2 ® Disclaimer Forward-Looking Statement Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “ |
|
| August 6, 2024 |
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update •Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA • Expanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distribution |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2024 Aquestive Therapeutics, Inc. |
|
| July 25, 2024 |
aqst-selfadministrations Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study Your publication date and time will appear here. |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2024 Aquestive Therapeutics, Inc. |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6,2024 Aquestive Therapeutics, Inc. |
|
| June 7, 2024 |
aqstcorppres0624 Advancing medicines. Solving problems. Improving lives. ©2024 Aquestive Therapeutics, Inc.1 Advancing medicines. Solving problems. Improving lives. Corporate Presentation June 2024 Advancing medicines. Solving problems. Improving lives. ©2024 Aquestive Therapeutics, Inc. Disclaimer 2 This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutic |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2024 Aquestive Therapeutics, Inc. |
|
| May 8, 2024 |
q12024supplementalearnin Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. First Quarter 2024 Earnings Supplemental Materials May 7, 2024 1 Advancing medicines. Solving problems. Improving lives. 2 ® Disclaimer Certain statements in this presentation include “forward-looking statements” within the meaning of the Private Securities Litig |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 Aquestive Therapeutics, Inc. |
|
| May 7, 2024 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. First Quarter 2024 Earnings Supplemental Materials May 7, 2024 1 Advancing medicines. Solving problems. Improving lives. 2 ® Disclaimer Certain statements in this presentation include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| May 7, 2024 |
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update •Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen® and other injectors used for the treatment of anaphylaxis •On track to complete Anaphylm temperature/pH study in second quarter 2024 •Received positive fee |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 Aquestive Therapeutics, Inc. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therapeuti |
|
| April 29, 2024 |
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film • Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5 • Announces immediate availability of Libervant 5mg, |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2024 Aquestive Therapeutics, Inc. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 24, 2024 |
Piper Sandler The date of this prospectus is April 23, 2024. TABLE OF CONTENTS Filed pursuant to Rule 424(b)(2) Registration No. 333-278498 PROSPECTUS Up to $100,000,000 Common Stock We previously entered into an Equity Distribution Agreement with Piper Sandler & Co., or Piper Sandler, dated September 11, 2019, as amended on March 26, 2021, or the Amended Equity Distribution Agreement, relating to shares of our common stock offered by this prospectus. In |
|
| April 24, 2024 |
Aquestive Therapeutics, Inc. Common Stock Preferred Stock Debt Securities TABLE OF CONTENTS Filed pursuant to Rule 424(b)(2) Registration No. 333-278498 PROSPECTUS Aquestive Therapeutics, Inc. $250,000,000 Common Stock Preferred Stock Debt Securities Warrants Rights Units From time to time, we may offer up to $250,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2024 Aquestive Therapeutics, Inc. |
|
| April 19, 2024 |
April 19, 2024 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 19, 2024 |
April 19, 2024 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 16, 2024 |
April 16, 2024 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 3, 2024 |
Exhibit 4.3 AQUESTIVE THERAPEUTICS, INC., AS ISSUER, AND [TRUSTEE], AS TRUSTEE, INDENTURE DATED AS OF , 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certifica |
|
| April 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Aquestive Therapeutics, Inc. |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 1, 2024 |
Web file:///C:/Users/rrodriguez/Downloads/Web(4).html 1 of 4 3/31/2024, 9:32 PM Web file:///C:/Users/rrodriguez/Downloads/Web(4).html 2 of 4 3/31/2024, 9:32 PM Web file:///C:/Users/rrodriguez/Downloads/Web(4).html 3 of 4 3/31/2024, 9:32 PM Web file:///C:/Users/rrodriguez/Downloads/Web(4).html 4 of 4 3/31/2024, 9:32 PM |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2024 Aquestive Therapeutics, Inc. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aquestive Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 03843E104 (CUSIP Number) March 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| March 21, 2024 |
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock Exhibit 99.2 Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) – Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announ |
|
| March 21, 2024 |
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Aquestive Therapeutics Announces Proposed Public Offering of Common Stock Warren, N.J., March 19, 2024 (GLOBE NEWSWIRE) – Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it intends to offe |
|
| March 21, 2024 |
16,666,667 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-254775 PROSPECTUS SUPPLEMENT (To Prospectus dated April 5, 2021) 16,666,667 Shares Common Stock We are offering 16,666,667 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “AQST.” On March 19, 2024, the last reported sale price of our |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2024 Aquestive Therapeutics, Inc. |
|
| March 21, 2024 |
Exhibit 1.1 Aquestive Therapeutics, Inc. (a Delaware corporation) 16,666,667 Shares of Common Stock UNDERWRITING AGREEMENT March 19, 2024 Leerink Partners LLC Piper Sandler & Co. as Representatives of the several Underwriters c/o Leerink Partners LLC 1301 Avenue of the Americas 12th Floor New York, New York 10019 c/o Piper Sandler & Co. 50 California Street, Suite 3100 San Francisco, California 94 |
|
| March 19, 2024 |
TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| March 15, 2024 |
pivotalstudytypecmeeting Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Pivotal Study and FDA Meeting Supplemental Slides March 2024 1 Advancing medicines. Solving problems. Improving lives. Disclaimer © 2024 Property of Aquestive Therapeutics, Inc. 2 This presentation and the accompanying oral commentary have been prepared by Aquest |
|
| March 15, 2024 |
9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 Aquestive Therapeutics, Inc. |
|
| March 15, 2024 |
a31424prproof • • • • • • Web https://distribute.notified.com/Preview/PnrArticlePreview?r=6875731&l=eng 1 of 8 3/14/2024, 5:08 PM Web https://distribute.notified.com/Preview/PnrArticlePreview?r=6875731&l=eng 2 of 8 3/14/2024, 5:08 PM • • • • • • • • • Web https://distribute.notified.com/Preview/PnrArticlePreview?r=6875731&l=eng 3 of 8 3/14/2024, 5:08 PM Anticipated Timing Pivotal PK Studies Suppor |
|
| March 5, 2024 |
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update •Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 million •Reaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024 •Reaffirms anticipated FDA decision on Libervant™ (diazepam) Buccal Film ap |
|
| March 5, 2024 |
9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2024 Aquestive Therapeutics, Inc. |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Ther |
|
| March 5, 2024 |
pharmanovialsaamendment0 LICENSE AND SUPPLY AGREEMENT AMENDMENT This LICENSE AND SUPPLY AMENDMENT (together with the Schedules hereto, this “Amendment”) is entered into as of 27 March 2023 (the “Effective Date of this Amendment”) by and between Aquestive Therapeutics, Inc. |
|
| March 5, 2024 |
Aquestive Therapeutics, Inc. Incentive Compensation Recovery Policy Aquestive Therapeutics, Inc. Incentive Compensation Recovery Policy I.Purpose The purpose of this Incentive Compensation Recovery Policy, as may be amended from time to time (the “Policy”), is to describe the circumstances under which the Covered Executives (as defined below) will be required to repay or return Incentive Compensation (as defined below) to Aquestive Therapeutics, Inc. (the “Company |
|
| March 5, 2024 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Q4 2024 Earnings Supplemental Materials March 5, 2024 1 Advancing medicines. Solving problems. Improving lives. 2 ® Disclaimer Certain statements in this presentation include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words su |
|
| February 14, 2024 |
AQST / Aquestive Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2024 |
As filed with the Securities and Exchange Commission on February 12, 2024 As filed with the Securities and Exchange Commission on February 12, 2024 Registration No. |
|
| February 12, 2024 |
Filing Fee Table, filed herewith. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aquestive Therapeutics, Inc. |
|
| December 13, 2023 |
30 Technology Drive Warren, NJ 07059 908.941.1900 aquestive.com December 12, 2023 VIA FEDERAL EXPRESS AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Jenn Do and Kevin Vaughn Re: Aquestive Therapeutics, Inc. Form 10K for the fiscal year ended December 31, 2022 Filed March 31, 2023 |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2023 Aquestive Therapeutics, Inc. |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 Aquestive Therapeutics, Inc. |
|
| December 5, 2023 |
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film •Commences initial Phase 3 study with first orally delivered epinephrine prodrug candidate •Reaffirms topline data anticipated in first quarter 2024 WARREN, N. |
|
| November 8, 2023 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Corporate Presentation November 2023 Advancing medicines. Solving problems. Improving lives. Disclaimer This presentation and the accompanying oral commentary has been prepared by Aquestive Therapeutics, Inc. (the “Company”, “our” or “us”) and contains forward-looking statements within t |
|
| November 8, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 Aquestive Therapeutics, Inc. |
|
| November 6, 2023 |
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update •Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data targeted for first quarter 2024 •Completes debt refinancing resulting in approximately $28 million of cash savings through June of 20 |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2023 Aquestive Therapeutics, Inc. |
|
| November 6, 2023 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Q3 2023 Earnings Supplemental Materials November 6, 2023 1 Advancing medicines. Solving problems. Improving lives. 2 ® Disclaimer Certain statements in this presentation include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therap |
|
| November 2, 2023 |
Exhibit 10.2 COLLATERAL AGREEMENT DATED AS OF NOVEMBER 1, 2023 AMONG AQUESTIVE THERAPEUTICS, INC., as Issuer, THE OTHER GRANTORS FROM TIME TO TIME PARTY HERETO, U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee, and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Collateral Agent TABLE OF CONTENTS Page Article I DEFINITIONS; RULES OF CONSTRUCTION 2 Section 1.1 Terms Defined Elsewhere 2 S |
|
| November 2, 2023 |
Aquestive Therapeutics Completes $45 Million Debt Refinancing Exhibit 99.1 Aquestive Therapeutics Completes $45 Million Debt Refinancing Warren, N.J., November X, 2023 – Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility. The Company redeemed its 12.5% seni |
|
| November 2, 2023 |
Exhibit 4.1 AQUESTIVE THERAPEUTICS, INC., as Issuer, and any Guarantor that becomes party hereto pursuant to Section 4.10 hereof 13.5% Senior Secured Notes due 2028 INDENTURE Dated as of November 1, 2023 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee and as Collateral Agent TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 SECTION 1.01. Definitions 1 SECTION |
|
| November 2, 2023 |
Exhibit 10.3 ROYALTY RIGHT AGREEMENT dated as of November 1, 2023 between AQUESTIVE THERAPEUTICS, INC. and THE PURCHASER NAMED HEREIN Table of Contents Page ARTICLE I RULES OF CONSTRUCTION AND DEFINED TERMS Section 1.1 Rules of Construction and Defined Terms 1 ARTICLE II ROYALTY RIGHT Section 2.1 Sale of Royalty Right 1 Section 2.2 Payment Procedures 1 Section 2.3 Information Rights 2 Section 2.4 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 Aquestive Therapeutics, Inc. |
|
| November 2, 2023 |
Exhibit 10.1 PURCHASE AGREEMENT dated November 1, 2023 between AQUESTIVE THERAPEUTICS, INC. and THE PURCHASER NAMED HEREIN $45,000,000 13.5% SENIOR SECURED NOTES DUE 2028 Table of Contents Page ARTICLE I INTRODUCTORY Section 1.1 Introductory 1 ARTICLE II RULES OF CONSTRUCTION AND DEFINED TERMS Section 2.1 Rules of Construction and Defined Terms 1 ARTICLE III SALE AND PURCHASE OF NOTES AND ROYALTY |
|
| October 10, 2023 |
Aquestive Therapeutics Provides Business Update Aquestive Therapeutics Provides Business Update •Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual Film •Reaffirms Q4 2023 Anaphylm pivotal phase 3 study start and Q1 2024 topline data readout •Outlines expected remaining activities for Anaphylm program prior to NDA submission •Indicates FDA review of Libervant™ (diazepam) Buccal Film on track with no open questions •Anticipates increasing 2023 revenue and decreasing non-GAAP adjusted EBITDA loss guidance in upcoming earnings release WARREN, N. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 9, 2023 Aquestive Therapeutics, Inc. |
|
| October 2, 2023 |
Aquestive Therapeutics, Inc. 2,750,000 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-274609 PROSPECTUS Aquestive Therapeutics, Inc. 2,750,000 Shares of Common Stock This prospectus relates to the resale of up to 2,750,000 shares of Aquestive Therapeutics, Inc. (the “Company,” “we,” “our” or “us”) common stock, par value $0.001 per share (the “Common Stock”), by the selling stockholder listed in this prospe |
|
| September 27, 2023 |
September 27, 2023 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| September 21, 2023 |
EX-FILING FEES Calculation of Filing Fee Tables FORM S-3 (Form Type) Aquestive Therapeutics, Inc. |
|
| September 21, 2023 |
As filed with the Securities and Exchange Commission on September 20, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 20, 2023 Registration No. |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2023 Aquestive Therapeutics, Inc. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2023 Aquestive Therapeutics, Inc. |
|
| August 11, 2023 |
corporatepresentation-au Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Corporate Presentation August 2023 1 Advancing medicines. Solving problems. Improving lives. Disclaimer This presentation and the accompanying oral commentary has been prepared by Aquestive Therapeutics, Inc. (the “Company”, “our” or “us”) and contains forward-lo |
|
| August 9, 2023 |
Filing Fee Table, filed herewith. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aquestive Therapeutics, Inc. |
|
| August 9, 2023 |
Exhibit 4.1 AQUESTIVE THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN Section 1. Purpose of the Plan. The purpose of the Plan is to assist the Company and its Subsidiaries in attracting and retaining valued Employees, Consultants and Non-Employee Directors by offering them a greater stake in the Company’s success and a closer identity with it, and to encourage ownership of the Company’s shares by su |
|
| August 9, 2023 |
As filed with the Securities and Exchange Commission on August 9, 2023 As filed with the Securities and Exchange Commission on August 9, 2023 Registration No. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2023 Aquestive Therapeutics, Inc. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therapeutic |
|
| August 7, 2023 |
aqst63023ex991earningsre Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • Submitted proposed pivotal trial protocol for Anaphylm™ (epinephrine) Sublingual Film to the FDA • Submitted an NDA to the FDA for Libervant™ (diazepam) Buccal Film for patients between two and five years of age • Reported 24% year-over-year growth in quarterly |
|
| August 7, 2023 |
Aquestive Therapeutics Q2 Earnings Supplemental Materials dated August 7, 2023 q22023earnings |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2023 Aquestive Therapeutics, Inc. |
|
| August 2, 2023 |
aqstwarrant 1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| August 2, 2023 |
Inducement Offer to Exercise Common Stock Purchase Warrants Letter Agreement dated August aqstwarrantinducementlet 1 AQUESTIVE THERAPEUTICS, INC. August 1, 2023 Holder of Common Stock Purchase Warrant Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Aquestive Therapeutics, Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), is pleased to offer to you the opportunity to exercise all of the Common Stock Purchase Warrant is |
|
| July 27, 2023 |
Exhibit 99.1 Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film •Reports positive topline data from latest pilot pharmacokinetic (PK) study •Plans to submit pivotal PK clinical study protocol to the FDA in early August •Anticipates commencement of its definitive pivotal PK clinical trial in the fourth quarter of 2023 WARREN, N.J., Jul |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2023 Aquestive Therapeutics, Inc. |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2023 Aquestive Therapeutics, Inc. |
|
| June 29, 2023 |
Advancing medicines. Solving problems. Improving lives. Corporate Presentation June 2023 1 Exhibit 99.1 Advancing medicines. Solving problems. Improving lives. Corporate Presentation June 2023 1 Disclaimer This presentation and the accompanying oral commentary has been prepared by Aquestive Therapeutics, Inc. (the “Company”, “our” or “us”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticip |
|
| June 29, 2023 |
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment Exhibit 99.2 Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment • Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of age • Appointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquesti |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2023 Aquestive Therapeutics, Inc. |
|
| May 31, 2023 |
Plasma Concentration (hr*pg/mL) Tmax (minutes) Cmax (pg/mL) anaphylmpressreleasesupp Plasma Concentration (hr*pg/mL) Tmax (minutes) Cmax (pg/mL) |
|
| May 31, 2023 |
aqstanaphylmpressrelease Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study Your publication date and time will appear here. |
|
| May 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2023 Aquestive Therapeutics, Inc. |
|
| May 2, 2023 |
q12023supplementalearnin Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Q1 2023 Earnings Supplemental Materials May 3, 2023 1 Advancing medicines. Solving problems. Improving lives. ® Disclaimer This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 which are |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 Aquestive Therapeutics, Inc. |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therapeuti |
|
| May 2, 2023 |
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update •Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™ •Raises full year 2023 revenue and non-GAAP adjusted EBITDA guidance •Reaffirms commitment to pursue early market access for Libervant™ (diazepam) Buccal F |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| April 18, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2023 Aquestive Therapeutics, Inc. |
|
| March 31, 2023 |
amend1purchaseagreement AMENDMENT NO. 1 TO PURCHASE AGREEMENT AMENDMENT NO. 1 TO PURCHASE AGREEMENT, dated as of August 6, 2021 (this “Amendment”), among AQUESTIVE THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the Purchasers signatory hereto. W I T N E S S E T H: WHEREAS, on November 3, 2020, the Company entered into the Purchase Agreement, (the “Existing Purchase Agreement”) with |
|
| March 31, 2023 |
indiviorceaamendment0323 THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Ther |
|
| March 31, 2023 |
aqst-assertiolicenseagre THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 Aquestive Therapeutics, Inc. |
|
| March 7, 2023 |
Exhibit 99.1 Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives •Pivotal study for AQST-109 (epinephrine sublingual film) on track to start in third quarter 2023 •Financial turnaround actions on track including 18% reduction of outstanding debt and the receipt of $20 million of non-dilutive capital in the first quart |
|
| March 7, 2023 |
q4earningsxsupplemental Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Q4 Earnings Supplemental Materials March 8, 2023 1 Advancing medicines. Solving problems. Improving lives. ® Disclaimer This presentation contains “forward-looking” statements that are based on the beliefs and assumptions and on information currently available to |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2023 Aquestive Therapeutics, Inc. |
|
| March 7, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2023 Aquestive Therapeutics, Inc. |
|
| March 7, 2023 |
aquestivecorporatepresen Advancing medicines. Solving problems. Improving lives. CONFIDENTIAL Advancing medicines. Solving problems. Improving lives. Corporate Presentation March 2023 1 Advancing medicines. Solving problems. Improving lives. CONFIDENTIAL ® Disclaimer This presentation contains “forward-looking” statements that are based on the beliefs and assumptions and on information currently a |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 Aquestive Therapeutics, Inc. |
|
| February 7, 2023 |
aquestiveamendedandresta AMENDED AND RESTATED BYLAWS OF AQUESTIVE THERAPEUTICS, INC. |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2023 Aquestive Therapeutics, Inc. |
|
| January 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 Aquestive Therapeutics, Inc. |
|
| January 24, 2023 |
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives Exhibit 99.1 Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives • Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 • Anticipates receipt in the coming months of FDA response to request for Libervant™ (diazepam) Buccal Film accelerated market access • Expects preliminary unaudited cash and cash |
|
| January 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aquestive Therapeutics, Inc. |
|
| January 18, 2023 |
As filed with the Securities and Exchange Commission on January 18, 2023 As filed with the Securities and Exchange Commission on January 18, 2023 Registration No. |
|
| January 3, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2022 Aquestive Therapeutics, Inc. |
|
| December 22, 2022 |
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film) ? FDA continues to indicate that the Company can conduct a comparability study rather than efficacy studies ? FDA provides clear guidance on approvability expectations for pharmacokinetic (PK) performance and patient administration attributes ? Company continues to anticipate a potential product launch in 2025 with an NDA submission in first half of 2024 WARREN, N. |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2022 Aquestive Therapeutics, Inc. |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2022 Aquestive Therapeutics, Inc. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2022 Aquestive Therapeutics, Inc. |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2022 Aquestive Therapeutics, Inc. |
|
| November 2, 2022 |
corporatedecknovember202 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. November 2022 Aquestive Therapeutics Corporate Presentation Advancing medicines. Solving problems. Improving lives. ® Forward-Looking Statement 2 © 2022 Property of Aquestive Therapeutics, Inc. This presentation includes forward-looking statements within the mean |
|
| November 2, 2022 |
q3earningssupplementalma Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. November 2022 Q3 2022 Earnings Supplemental Materials Advancing medicines. Solving problems. Improving lives. ® Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1 |
|
| November 1, 2022 |
atnahspharmauklimitedlic THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. |
|
| November 1, 2022 |
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update •Reported positive data from EPIPHAST II trial comparing AQST-109 (epinephrine sublingual film) to EpiPen® 0.3mg (single dose) and AQST-109 to epi 0.3mg IM injection (repeat dose) •Scheduled End-of-Phase 2 (EoP2) meeting with FDA on AQST-109 for fourth quarter 2022 •Generated over $25 mill |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 Aquestive Therapeutics, Inc. |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therap |
|
| October 27, 2022 |
a5889161releasexpreview Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc. |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 Aquestive Therapeutics, Inc. |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2022 Aquestive Therapeutics, Inc. |
|
| October 24, 2022 |
a5880806releasexpreview Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims WARREN, N. |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 11, 2022 Aquestive Therapeutics, Inc. |
|
| October 11, 2022 |
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film ? FDA?s End-of-Phase 2 written response provides positive feedback related to Chemistry, Manufacturing, and Controls (CMC) to support future NDA filing ? Supports approach to characterizing Aquestive?s proprietary novel prodrug form of epinephrine API ? Confirms Agency alignment on planned stability packages for both API and Drug Product ? FDA End-of-Phase 2 meeting for clinical feedback scheduled for later this quarter WARREN, N. |
|
| September 28, 2022 |
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant? (diazepam) Buccal Film for European and MENA Markets WARREN, N. |
|
| September 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2022 Aquestive Therapeutics, Inc. |
|
| September 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 27, 2022 Aquestive Therapeutics, Inc. |
|
| September 27, 2022 |
Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen? ? AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen? Tmax of 22. |
|
| September 27, 2022 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. September 2022 EPIPHAST II Trial Results Supplemental Materials 1 Advancing medicines. Solving problems. Improving lives. ? Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words su |
|
| September 13, 2022 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. September 2022 Aquestive Therapeutics H.C. Wainwright Advancing medicines. Solving problems. Improving lives. ? Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?belie |
|
| September 13, 2022 |
Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board WARREN, N. |
|
| September 13, 2022 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. September 2022 Aquestive Therapeutics Corporate Presentation Advancing medicines. Solving problems. Improving lives. ? Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as |
|
| September 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2022 Aquestive Therapeutics, Inc. |
|
| September 7, 2022 |
Piper Sandler The date of this prospectus supplement is September 7, 2022. TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-254775 PROSPECTUS SUPPLEMENT (to Prospectus dated April 5, 2021) Up to $35,000,000 ? Common Stock We previously entered into an Equity Distribution Agreement with Piper Sandler & Co., or Piper Sandler, dated September 11, 2019, as amended on March 26, 2021, or the Amended Equity Distribution Agreement, relating to shares of ou |
|
| September 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 7, 2022 Aquestive Therapeutics, Inc. |
|
| August 31, 2022 |
Aquestive Therapeutics Receives FDA Tentative Approval for Libervant? (diazepam) Buccal Film ? Libervant provided tentative approval from the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity ? Libervant U. |
|
| August 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2022 Aquestive Therapeutics, Inc. |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 23, 2022 Aquestive Therapeutics, Inc. |
|
| August 10, 2022 |
Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space ?Appoints Timothy E. |
|
| August 10, 2022 |
AQUESTIVE THERAPEUTICS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN Adopted by the Compensation Committee of the Board of Directors July 29, 2022 2 AQUESTIVE THERAPEUTICS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN Section 1. Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement mate |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2022 Aquestive Therapeutics, Inc. |
|
| August 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2022 Aquestive Therapeutics, Inc. |
|
| August 3, 2022 |
earningsuppupdated Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. August 2022 Aquestive Therapeutics Q2 2022 Earnings Supplemental Materials Advancing medicines. Solving problems. Improving lives. ® Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation |
|
| August 3, 2022 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. August 2022 Aquestive Therapeutics Corporate Presentation Advancing medicines. Solving problems. Improving lives. ? Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?b |
|
| August 2, 2022 |
Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update •Completed EPIPHAST trial successfully demonstrating rapid and significant epinephrine exposure under a variety of real-world conditions after administration of AQST-109 (epinephrine sublingual film) •Initiated EPIPHAST II trial, comparing AQST-109 to epinephrine 0.3mg IM injection (repea |
|
| August 2, 2022 |
1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of July 15, 2022 (the “Effective Date”) by and between Aquestive Therapeutics, Inc. |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 Aquestive Therapeutics, Inc. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38599 Aquestive Therapeutic |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2022 Aquestive Therapeutics, Inc. |
|
| July 15, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 14, 2022 Aquestive Therapeutics, Inc. |
|
| July 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2022 Aquestive Therapeutics, Inc. |
|
| July 11, 2022 |
Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST- 109 Epinephrine Oral Film ? Study results for the sublingual administration of AQST-109 epinephrine oral film after consuming a peanut butter sandwich demonstrates consistent Tmax of 12 minutes ? Study results for swallowing AQST-109 whole immediately with water showed an unexpectedly high level of gastrointestinal absorption ? EPIPHAST II, a crossover study, is now underway, comparing AQST-109 to epi 0. |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2022 Aquestive Therapeutics, Inc. |
|
| June 16, 2022 |
Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film ? AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development ? Fastest median time to maximum concentration (Tmax) in studies to date at 12 minutes ? Study continues to show AQST-109 is safe and well tolerated ? Head-to-head comparison study to EpiPen? scheduled to commence in third quarter 2022 ? On track to request End-of-Phase 2 meeting with FDA in fourth quarter 2022 and thereafter to commence pivotal PK study ? Remaining data from Part 3 expected to be reported in early third quarter 2022 WARREN, N. |
|
| June 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2022 Aquestive Therapeutics, Inc. |
|
| June 16, 2022 |
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. June 2022 Aquestive Therapeutics Corporate Presentation Advancing medicines. Solving problems. Improving lives. ? Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?bel |
|
| June 8, 2022 |
[The remainder of this page has been intentionally left blank.] Exhibit 1.1 June 6, 2022 Aquestive Therapeutics, Inc. 30 Technology Drive Warren, New Jersey 07059 Attention: Daniel Barber President and Chief Executive Officer Email: [email protected] Dear Mr. Barber: This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners, as the sole placement agent (?Placement Agent?), and Aquestive Therapeutics, Inc., a company or |
|
| June 8, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 6, 2022, between Aquestive Therapeutics, Inc., a corporation incorporated under the laws of the state of Delaware (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers? |
|
| June 8, 2022 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-254775 PROSPECTUS SUPPLEMENT (To Prospectus dated April 5, 2021) ? 4,850,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 4,000,000 Shares of Common Stock Warrants to Purchase up to 8,850,000 Shares of Common Stock We are offering on a ?best efforts? basis 4,850,000 shares (the ?Shares?) of our common stock, $0 |
|
| June 8, 2022 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT AQUESTIVE THERAPEUTICS, INC. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT AQUESTIVE THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: June 8, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
